Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anawalt, B. D.
Right arrow Articles by Matsumoto, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anawalt, B. D.
Right arrow Articles by Matsumoto, A. M.

Journal of Andrology, Vol 20, Issue 3 407-414, Copyright © 1999 by The American Society of Andrology

JOURNAL ARTICLE

A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations

B. D. Anawalt, R. A. Bebb, W. J. Bremner and A. M. Matsumoto
Department of Medicine of the University of Washington, USA.

Studies using exogenous high-dosage testosterone (T) or a combination regimen of physiologic T plus high-dosage levonorgestrel (LNG) administration in normal men have shown that oligoazoospermia (<3 million/mL) or azoospermia can be achieved in the majority of the men. However, these hormonal regimens have been associated with significant weight gain and suppression of serum high-density lipoprotein (HDL) cholesterol levels. We hypothesized that a combination of physiologic exogenous testosterone and lower dosage LNG would result in uniform severe oligoazoospermia or azoospermia in normal men but would cause fewer adverse metabolic side effects. We conducted a randomized, placebo-controlled, single-blind trial comparing 6 months of T enanthate (100 mg IM, weekly) plus LNG, 125 microg by mouth, daily (LNG 125; n = 18) or LNG, 250 microg by mouth, daily (LNG 250; n = 18) and compared these regimens with our previous study of the same dosage of T enanthate combined with placebo LNG (LNG 0; n = 18) or with 500 mg of LNG (LNG= 500; n = 18). All three combination regimens of T enanthate and LNG suppressed spermatogenesis more rapidly and resulted in significantly more uniform severe oligoazoospermia (<1 million/mL) than the T-alone regimen. Severe oligoazoospermia was achieved in 89% of the LNG 125, 89% of the LNG 250, and 78% of the LNG 500 groups, respectively, versus 56% of the men in LNG 0 (P < 0.05 for the combination groups vs. LNG 0), but there were no significant differences between the combination regimens (P = NS). All four groups gained significant weight compared with their baselines, although the gain tended to be greater as the dosage of LNG increased (2.0+/-0.9, 2.9+/-1.1, 3.6+/-1.0, and 5.4+/-1.0 kg gained, compared with baseline in the LNG 0, 125, 250, and 500 groups respectively; P < 0.05 compared with baseline). Serum levels of HDL cholesterol decreased in all of the groups, but the effect was larger as the dosage of LNG increased (4+/-4% vs. 13+/-4%, 20+/-3%, and 22+/-4% decrease in HDL levels from baseline in the LNG 0, LNG 125, LNG 250, and LNG 500 groups respectively; P = 0.06 for LNG 125 compared with LNG 0, and P < 0.05 for LNG 250 and LNG 500 compared with LNG 0). We conclude that 1) the combination of physiologic exogenous T enanthate and LNG suppresses spermatogenesis more effectively than T enanthate alone and that 2) the combination regimen of T enanthate plus lower dosage LNG suppresses sperm production comparably to T enanthate plus higher dosage LNG, while causing less weight gain and HDL cholesterol suppression. A combination regimen of physiologic testosterone plus a low dosage of levonorgestrel offers great promise as a safe and effective male contraceptive regimen.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
S. T. Page, J. K. Amory, and W. J. Bremner
Advances in Male Contraception
Endocr. Rev., June 1, 2008; 29(4): 465 - 493.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, R. S. Swerdloff, B. D. Anawalt, R. A. Anderson, W. J. Bremner, J. Elliesen, Y.-Q. Gu, W. M. Kersemaekers, Robert. I. McLachlan, M. C. Meriggiola, et al.
Determinants of the Rate and Extent of Spermatogenic Suppression during Hormonal Male Contraception: An Integrated Analysis
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1774 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Wang, Y.-G. Cui, X.-H. Wang, Y. Jia, A. Sinha Hikim, Y.-H. Lue, J.-S. Tong, L.-X. Qian, J.-H. Sha, Z.-M. Zhou, et al.
Transient Scrotal Hyperthermia and Levonorgestrel Enhance Testosterone-Induced Spermatogenesis Suppression in Men through Increased Germ Cell Apoptosis
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3292 - 3304.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
J. K. Amory, S. T. Page, B. D. Anawalt, A. D. Coviello, A. M. Matsumoto, and W. J. Bremner
Elevated End-of-Treatment Serum INSL3 Is Associated With Failure to Completely Suppress Spermatogenesis in Men Receiving Male Hormonal Contraception
J Androl, July 1, 2007; 28(4): 548 - 554.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
A. Qoubaitary, C. Meriggiola, C. M. Ng, L. Lumbreras, S. Cerpolini, G. Pelusi, P. D. Christensen, L. Hull, R. S. Swerdloff, and C. Wang
Pharmacokinetics of Testosterone Undecanoate Injected Alone or in Combination With Norethisterone Enanthate in Healthy Men
J Androl, November 1, 2006; 27(6): 853 - 867.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
K. L. Matthiesson and R. I. McLachlan
Male hormonal contraception: concept proven, product in sight?
Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Wang, X. H. Wang, A. L. Nelson, K. K. Lee, Y. G. Cui, J. S. Tong, N. Berman, L. Lumbreras, A. Leung, L. Hull, et al.
Levonorgestrel Implants Enhanced the Suppression of Spermatogenesis by Testosterone Implants: Comparison between Chinese and Non-Chinese Men
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 460 - 470.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Lue, C. Wang, Y.-X. Liu, A. P. S. Hikim, X.-S. Zhang, C.-M. Ng, Z.-Y. Hu, Y.-C. Li, A. Leung, and R. S. Swerdloff
Transient Testicular Warming Enhances the Suppressive Effect of Testosterone on Spermatogenesis in Adult Cynomolgus Monkeys (Macaca fascicularis)
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. L. Matthiesson, P. G. Stanton, L. O'Donnell, S. J. Meachem, J. K. Amory, R. Berger, W. J. Bremner, and R. I. McLachlan
Effects of Testosterone and Levonorgestrel Combined with a 5{alpha}-Reductase Inhibitor or Gonadotropin-Releasing Hormone Antagonist on Spermatogenesis and Intratesticular Steroid Levels in Normal Men
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5647 - 5655.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
B. D. Anawalt, J. K. Amory, K. L. Herbst, A. D. Coviello, S. T. Page, W. J. Bremner, and A. M. Matsumoto
Intramuscular Testosterone Enanthate Plus Very Low Dosage Oral Levonorgestrel Suppresses Spermatogenesis Without Causing Weight Gain in Normal Young Men: A Randomized Clinical Trial
J Androl, May 1, 2005; 26(3): 405 - 413.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. D. Coviello, A. M. Matsumoto, W. J. Bremner, K. L. Herbst, J. K. Amory, B. D. Anawalt, P. R. Sutton, W. W. Wright, T. R. Brown, X. Yan, et al.
Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men with Testosterone-Induced Gonadotropin Suppression
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2595 - 2602.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. J. Hay, B. M. Brady, M. Zitzmann, K. Osmanagaoglu, P. Pollanen, D. Apter, F. C. W. Wu, R. A. Anderson, E. Nieschlag, P. Devroey, et al.
A Multicenter Phase IIb Study of a Novel Combination of Intramuscular Androgen (Testosterone Decanoate) and Oral Progestogen (Etonogestrel) for Male Hormonal Contraception
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2042 - 2049.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. L. Matthiesson, J. K. Amory, R. Berger, A. Ugoni, R. I. McLachlan, and W. J. Bremner
Novel Male Hormonal Contraceptive Combinations: The Hormonal and Spermatogenic Effects of Testosterone and Levonorgestrel Combined with a 5{alpha}-Reductase Inhibitor or Gonadotropin-Releasing Hormone Antagonist
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 91 - 97.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
A. D. Coviello, W. J. Bremner, A. M. Matsumoto, K. L. Herbst, J. K. Amory, B. D. Anawalt, X. Yan, T. R. Brown, W. W. Wright, B. R. Zirkin, et al.
Intratesticular Testosterone Concentrations Comparable With Serum Levels Are Not Sufficient to Maintain Normal Sperm Production in Men Receiving a Hormonal Contraceptive Regimen
J Androl, November 1, 2004; 25(6): 931 - 938.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
Y.-L. Gui, C.-H. He, J. K. Amory, W. J. Bremner, E-X. Zheng, J. Yang, P.-J. Yang, and E.-S. Gao
Male Hormonal Contraception: Suppression of Spermatogenesis by Injectable Testosterone Undecanoate Alone or With Levonorgestrel Implants in Chinese Men
J Androl, September 1, 2004; 25(5): 720 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y.-q. Gu, J.-s. Tong, D.-z. Ma, X.-h. Wang, D. Yuan, W.-h. Tang, and W. J. Bremner
Male Hormonal Contraception: Effects of Injections of Testosterone Undecanoate and Depot Medroxyprogesterone Acetate at Eight-Week Intervals in Chinese Men
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2254 - 2262.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. I. McLachlan, D. M. Robertson, E. Pruysers, A. Ugoni, A. M. Matsumoto, B. D. Anawalt, W. J. Bremner, and C. Meriggiola
Relationship between Serum Gonadotropins and Spermatogenic Suppression in Men Undergoing Steroidal Contraceptive Treatment
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 142 - 149.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-Labate, B. Kirsch, A. Bertaccini, C. Pelusi, and G. Pelusi
Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5818 - 5826.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo
A Review of Androgen-Progestin Regimens for Male Contraception
J Androl, July 1, 2003; 24(4): 466 - 483.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
F. C. W. Wu and A. von Eckardstein
Androgens and Coronary Artery Disease
Endocr. Rev., April 1, 2003; 24(2): 183 - 217.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. A. Anderson and D. T. Baird
Male Contraception
Endocr. Rev., December 1, 2002; 23(6): 735 - 762.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R.A. Anderson, Z.M. van der Spuy, O.A. Dada, S.K. Tregoning, P.M. Zinn, O.A. Adeniji, T.A. Fakoya, K.B. Smith, and D.T. Baird
Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone
Hum. Reprod., November 1, 2002; 17(11): 2869 - 2877.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
M. C. Meriggiola, A. Costantino, W. J. Bremner, and A. M. Morselli-Labate
Higher Testosterone Dose Impairs Sperm Suppression Induced by a Combined Androgen-Progestin Regimen
J Androl, September 1, 2002; 23(5): 684 - 690.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. T. G. Gonzalo, R. S. Swerdloff, A. L. Nelson, B. Clevenger, R. Garcia, N. Berman, and C. Wang
Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3562 - 3572.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Anderson, D. Kinniburgh, and D. T. Baird
Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. M. Cherrier, B. D. Anawalt, K. L. Herbst, J. K. Amory, S. Craft, A. M. Matsumoto, and W. J. Bremner
Cognitive Effects of Short-Term Manipulation of Serum Sex Steroids in Healthy Young Men
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3090 - 3096.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. C. Meriggiola, W. J. Bremner, A. Costantino, A. Bertaccini, A. M. Morselli-Labate, D. Huebler, G. Kaufmann, M. Oettel, and C. Flamigni
Twenty-One Day Administration of Dienogest Reversibly Suppresses Gonadotropins and Testosterone in Normal Men
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2107 - 2113.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. M. Hair, K. Kitteridge, D. B. O'Connor, and F. C. W. Wu
A Novel Male Contraceptive Pill-Patch Combination: Oral Desogestrel and Transdermal Testosterone in the Suppression of Spermatogenesis in Normal Men
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5201 - 5209.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Kamischke, S. Venherm, D. Plöger, S. von Eckardstein, and E. Nieschlag
Intramuscular Testosterone Undecanoate and Norethisterone Enanthate in a Clinical Trial for Male Contraception
J. Clin. Endocrinol. Metab., January 1, 2000; 86(1): 303 - 309.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by The American Society of Andrology.